Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$4.69
-0.05-1.05%
At close: -
$4.66
-0.03-0.64%
After Hours: 9:29 AM EDT
Comments
Loading...
OnKure Therapeutics Analyst Ratings and Price Targets | NASDAQ:OKUR | Benzinga
OnKure Therapeutics Inc has a consensus price target of $32.25 based on the ratings of 4 analysts. The high is $34 issued by HC Wainwright & Co. on March 18, 2025. The low is $30 issued by Oppenheimer on March 11, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Oppenheimer, and Jones Trading on March 18, 2025, March 11, 2025, and January 28, 2025, respectively. With an average price target of $32 between HC Wainwright & Co., Oppenheimer, and Jones Trading, there's an implied 586.70% upside for OnKure Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Oppenheimer
Jones Trading
Leerink Partners
1calculated from analyst ratings
Analyst Ratings for OnKure Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/18/2025 | Buy Now | 629.61% | HC Wainwright & Co. | Robert Burns42% | $40 → $34 | Maintains | Buy | Get Alert |
| 03/11/2025 | Buy Now | 543.78% | Oppenheimer | Matt Biegler7% | $35 → $30 | Maintains | Outperform | Get Alert |
| 01/28/2025 | Buy Now | 586.7% | Jones Trading | Soumit Roy38% | → $32 | Initiates | → Buy | Get Alert |
| 12/05/2024 | Buy Now | 608.15% | Leerink Partners | Andrew Berens48% | → $33 | Initiates | → Outperform | Get Alert |
| 11/08/2024 | Buy Now | 758.37% | HC Wainwright & Co. | Robert Burns42% | $40 → $40 | Reiterates | Buy → Buy | Get Alert |
| 10/17/2024 | Buy Now | 758.37% | HC Wainwright & Co. | Robert Burns42% | → $40 | Assumes | → Buy | Get Alert |
| 10/10/2024 | Buy Now | 651.07% | Oppenheimer | Matt Biegler7% | → $35 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for OnKure Therapeutics (OKUR) stock?
The latest price target for OnKure Therapeutics (NASDAQ:OKUR) was reported by HC Wainwright & Co. on March 18, 2025. The analyst firm set a price target for $34.00 expecting OKUR to rise to within 12 months (a possible 629.61% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for OnKure Therapeutics (OKUR)?
The latest analyst rating for OnKure Therapeutics (NASDAQ:OKUR) was provided by HC Wainwright & Co., and OnKure Therapeutics maintained their buy rating.
When was the last upgrade for OnKure Therapeutics (OKUR)?
There is no last upgrade for OnKure Therapeutics
When was the last downgrade for OnKure Therapeutics (OKUR)?
There is no last downgrade for OnKure Therapeutics.
When is the next analyst rating going to be posted or updated for OnKure Therapeutics (OKUR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of OnKure Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for OnKure Therapeutics was filed on March 18, 2025 so you should expect the next rating to be made available sometime around March 18, 2026.
Is the Analyst Rating OnKure Therapeutics (OKUR) correct?
While ratings are subjective and will change, the latest OnKure Therapeutics (OKUR) rating was a maintained with a price target of $40.00 to $34.00. The current price OnKure Therapeutics (OKUR) is trading at is $4.66, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.